 Ovid Therapeutics NASDAQ:OVID had its target price lifted by equities researchers at Citigroup from 8.00 to 9.00 in a note issued to investors on Tuesday, The Fly reports. The firm presently has a buy rating on the stock. Citigroups target price would indicate a potential upside of 22.45 from the companys current price. Other research ... 